KLK3 and neoplasm: Atorvastatin did not significantly reduce PSA or Ki-67 (a marker of cellular proliferation) overall compared to placebo, but a significant decreasing trend in tumor proliferation marker Ki-67 by the length of atorvastatin exposure was observed.